Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 25 or more amino acid residues in defined sequence
Reexamination Certificate
2005-12-06
2005-12-06
Moran, Majorie (Department: 1631)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
25 or more amino acid residues in defined sequence
C514S012200
Reexamination Certificate
active
06972319
ABSTRACT:
This invention provides novel peptides that function in vivo to stimulate insulin release from pancreatic beta cells in a glucose-dependent fashion. These insulin secretagogue peptides are shown to stimulate insulin release in rat islet cells in vitro, and in vivo. The peptides of the present invention provide a new therapy for patients with decreased endogenous insulin secretion, in particular type 2 diabetics. In particular, the invention is a polypeptide selected from a specific group of VIP/PACAP-related polypeptides, or functional equivalents thereof. The invention is also directed to a method of treating a metabolic disease in a mammal comprising administering a therapeutically effective amount of the insulin secretagogue peptides to said mammal. Also disclosed are methods of making the peptides, both recombinant and synthetic.
REFERENCES:
patent: 5234907 (1993-08-01), Bolin
patent: 5376637 (1994-12-01), Sawai et al.
patent: 5677419 (1997-10-01), Bolin
patent: 0 796 867 (1997-09-01), None
patent: WO 91/14786 (1991-10-01), None
patent: WO 98/02453 (1998-01-01), None
patent: WO 99/47159 (1999-09-01), None
patent: WO 00/05260 (2000-02-01), None
Gourlet et al., Vasoactive intestinal peptide modification at position 22 allows discrimination between receptor subtypes. European Journal of Phamacology, vol. 348, No. 1, May 1, 1998, pp. 95-99.
Inagaki et al., Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells. Proceedings of the National Academy of Sciences of the United States, vol. 91, No. 7, 1994, pp. 2679-2683.
Gourlet, et al., C-Terminally Shortened Pituitary Adenylate Cyclase-Activating Peptides (PACAP) Descriminate PACAP I PACAP II-VIP1 and PACAP II-VIP2 Recombinant Receptors. Regulatory Peptides, NL, Elsevier Science BV, vol. 62, No. 2/03, 1996, pp. 125-130.
Gourlet, et al, Analogues of VIP, helodermin and PACAP discriminate between rat and human VIP1 and VIP2 receptors. Annals of the New York Academy of Sciences, vol. 865, Dec. 11, 1998, pp. 247-252.
Dickinson et al., VIP and PACAP: very important in pain?, Trends in Pharmacological Sciences, GB, Elsevier Trends Journal, Cambridge, vol. 20, No. 8, Aug. 1, 1999, pp. 324-329.
Harmar, et al., International union of pharmacology, XVIII, Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylte cyclase-activating polypeptide, Pharmacological Reviews, vol. 50, No. 2, Jun. 1998 pp. 265-270.
Gourlet et al., The long acting vasoactive intestinal polypeptide agonist R025-1553IS highly selective of the VIP2 Receptor Subclass, Peptides, US, Elmsford, vol. 18, No. 3, 1997, pp. 403-408.
Robberecht et al., Interet Des Recepteurs Recombinants Dans L'Elaboration D'Agonistes et D'Antagonistes Des Recepteurs Du VIP Et Du PACAP. Journal de pharmacie de Belgique, pp. 165-169.
Nokihara et al., Receptor recognition of PACAP and VIP examined by binding studies production and biological actions both in vivo and in vitro by means of selective residue substitution, Edinburgh, Sep. 8-13, 1996, West Midlands: Mayflower Scientific, GB, vol. Symp. 24, 1996, pp. 63-66.
Gourlet et al., Addition of the (28-38) peptide sequence of PACAP to the VIP sequence modifies peptide selectively and efficacy, International Journal of peptide and protein research, DK, Munksgaard, Copenhagen, vol. 48, No. ,4 Oct. 1, 1996, pp. 391-396.
Pohl, Molecular cloning of the helodermin and exedin-4 cDNAs in the lizard: relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues, Journal of Biogical Chemistry, vol. 273, No. 16, Apr. 17, 1998, pp. 9778-9784.
Bolin, et al, Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma, Biopolymers 1995;37(2):57-66.
Yokota, et al, PACAP stimulates glucose output from the perfursed rat liver. Peptides 16:55-60, 1995.
Straub et al., A wortmannin-sensitive signal transduction pathway is involved in the stimulation of insulin release by vasoactive intetinal polypeptide and pituitary adenylate cyclase-activating polypeptide, J Biol Chem 271: 1660-1668, 1996.
Sekiguchi, et al., Glycogenolytic activity of pituitary adenylate cyclase activating polypeptide (PACAP) in vivo and in vitro Life Sci vol. 55, No. 15, pp. 1219-1228, 1994.
Filipsson, et al, PACAP and PACAP receptors in insulin producing tissues: localization and effects. Regul Pept 74: 167-175, 1998.
Nicole et al., Identification of key resideus for interaction of vasoactive intestinal peptide with human VPACI, and VPAC2 Receptors and Development of a highly selective of a highly selective VPAC1 receptor agonist. The Journal of Biological Chemistry vol. 275, No. 31, pp 24003-24012, (2000).
Xia et al., Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor, J Pharmacol Exp Ther. May 1997; 281(2): 629-33.
Yada et al., Pituitary adenylate cyclase activating polypeptide is an extraordinarily potent intra-pancreatic regulator of insulin secretion from islet beta-cells. J Biol Chem vol. 269, No. 2, Issue of Jan. 14, pp 1290-1293, 1994.
Vandermeers et al., Antagonistic properties are shifted back to agonist properties by further N-terminal shortening of pituitary adenylate-cyclase-activating peptides in human neuroblastoma NB-OK-1 Cell membranes. (Eur. J. Biochem. 208, 815-819 (1992).
Komatsu et al., Augmentation of insulin release by glucose in the absence of extracellular ca2+ (Diabetes, vol. 46, Dec. 1997), pp. 1928-1938.
Pan Clark
Shanafelt Armen B.
Tsutsumi Manami
Bayer Pharmaceuticals Corporation
Moran Majorie
Pellegrino Susan M.
LandOfFree
Pituitary adenylate cyclase activating peptide... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pituitary adenylate cyclase activating peptide..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pituitary adenylate cyclase activating peptide... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3509324